Parvovirus B19 seroprevalence in Turkish blood donors
Background/aim: Parvovirus risk in blood transfusion has become a popular research topic since there are limited data on parvovirus
seroprevalence in blood donors in Turkey. The aim of this study was to investigate parvovirus seroprevalence in blood donors in Turkey.
Materials and methods: Blood samples of 988 blood donors admitted to a university blood bank were obtained for parvovirus B19 IgM
and IgG detection. The samples were analyzed using the ELISA method.
Results: IgM positivity of 3.92% and IgG positivity of 58.9% was detected in the blood samples. Parvovirus IgM positivity was found to
be the highest in the age group of 41-50 years (P = 0.045) and IgG positivity was detected to be the highest in the age group of 31-40
years (P < 0.001). Parvovirus IgG positivity was significantly higher in women (P = 0.041). However, there was no difference regarding
parvovirus IgM positivity in terms of sex (P = 0.245).
Conclusion: Although this study does not represent the whole country, it is still the largest investigation carried out on the topic in
Turkey and the obtained results are generally similar to those of European countries. Therefore, it is thought that the results obtained
from this study may be supportive for the first steps regarding plasma fractionation, which will soon begin in Turkey.
___
- Gallinella G. Parvovirus B19 achievements and challenges.
ISRN Virol 2013; 2013: 898730.
- Kaufmann B, Simpson AA, Rossmann MG. The structure of
human parvovirus B19. P Natl Acad Sci USA 2004; 101, 32:
11628-11633.
- Mossong J, Hens N, Friederichs V, Davidkin I, Broman M,
Litwinska B, Siennicka J, Trzcinska A, Van Damme P, Beutels
P et al. Parvovirus B19 infection in five European countries:
seroepidemiology, force of infection and maternal risk of
infection. Epidemiol Infect 2008; 136: 1059-1068.
- Corcoran A, Doyle S. Advances in the biology, diagnosis and
host-pathogen interactions of parvovirus B19. J Med Microbiol
2004; 53: 459-475.
- Marano G, Vaglio S, Pupella S, Facco G, Calizzani G, Candura
F, Liumbruno GM, Grazzini G. Human parvovirus B19 and
blood product safety: a tale of twenty years of improvements.
Blood Transfus 2015; 13: 184-196.
- Siegl G, Cassinotti P. Presence and significance of parvovirus
B19 in blood and blood products. Biologicals 1998; 26: 89-94.
- Azzi A, Morfini M, Mannucci PM. The transfusion-associated
transmission of parvovirus B19. Transfus Med Rev 1999; 13:
194-204.
- Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro
K. Symptomatic parvovirus B19 infection caused by blood
component transfusion. Transfusion 2011; 51: 1887-1895.
- Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden
M, Hildebrandt M, Jansen B, Montag-Lessing T, Offergeld R et
al. Parvovirus B19 revised. Transfus Med Hemother 2010; 37:
339-350.
- Goeyvaerts N, Hens N, Ogunjimi B, Aerts M, Shkedy Z, Van
Damme P, Beutels P. Estimating infectious disease parameters
from data on social contacts and serological status. J Royal Stat
Soc 2010; 13: 255-277.
- US Food and Drug Administration. Guidance for Industry:
Nucleic Acid Testing (NAT) To Reduce the Possible Risk of
Parvovirus B19 Transmission by Plasma-Derived Products.
Washington, DC, USA: FDA; 2009.
- Council of Europe. Human Plasma (Pooled and Treated for
Virus Inactivation), Monograph 1646. Strasbourg, France:
Council of Europe; 2008.
- Lefrere JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas
I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S. Persistent
B19 infection in immunocompetent individuals: implications
for transfusion safety. Blood 2005; 106: 2890-2895.
- Türk Dağı H, Özdemir M, Baykan M, Baysal B. Investigation of
parvovirus B19 seroprevalence in various age groups in Central
Anatolia Region, Turkey. Mikrobiyol Bul 2010; 44: 467-472.
- Motor VK, Arıca S, Motor S, Yılmaz N, Evirgen Ö, İnci
M, Gökçe C, Önlen Y. Investigation of parvovirus B19
seroprevalence, endothelin-1 synthesis, and nitric oxide levels
in the etiology of essential hypertension. Clin Exp Hypertens
2012; 34: 217-221.
- Erden S, Keskin F, Çiftçi S, Çınar S, Deniz G. The relationship
between parvovirus B19 and Hashimoto’s thyroiditis. Turkiye
Klinikleri J Med Sci 2013; 33: 98-102.
- Motor VK, Üstün N, Evirgen Ö, İnci M, Yula E, Önlen Y. The
seropositivity of parvovirus B19 in patients with ankylosing
spondylitis. Turk J Phys Med Rehab 2014; 60: 37-40.
- Gaggero A, Rivera J, Colquin E, Larranaga CE, Leon O,
Diaz P, Gaggero N. Seroprevalence of IgG antibodies against
parvovirus B19 among blood donors from Santiago, Chile. Rev
Med Chil 2007; 135: 443-448.
- Siennicka J, Stefanoff P, Trzcinska A, Rosinska M, Litwinska
B. Seroprevalence study of parvovirus B19 in Poland. Przeglad
Epidemiol 2006; 60: 571-580.
- Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill
W. The age-specific prevalence of human parvovirus immunity
in Victoria, Australia compared with other parts of the world.
Epidemiol Infect 2000; 124: 449-457.
- Cohen BJ, Buckley MM. The prevalence of antibody to human
parvovirus B19 in England and Wales. J Med Microbiol 1988;
25: 151-153.
- Manaresi E, Gallinella G, Marselli Labate AM, Zucchelli P,
Zaccarelli D, Ambretti S, Delbarba S, Zerbini M, Musiani
M. Seroprevalence of IgG against conformational and linear
capsid antigens of parvovirus B19 in Italian blood donors.
Epidemiol Infect 2004; 132: 857-862.
- Bhattarakasol P, Pancharoen C, Kowitdamrong E,
Thammaborvorn R, Mungmee V. Prevalence of parvovirus B19
infection in Thai young adults. Southeast Asain J Trop Med
Public Health 2003; 34: 585-588.
- Ooi SL, Hooi PS, Chua BH, Lam SK, Chua KB. Seroprevalence
of human parvovirus B19 infection in an urban population in
Malaysia. Med J Malaysia 2002; 57: 97-103.
- Munoz S, Alonso MA, Fernandez MJ, Munoz JL, Garcia-
Rodriguez JA. Seroprevalence versus parvovirus B19 in blood
donors. Enferm Infecc Microbiol Clin 1998; 16: 161-162.
- Letaief M, Vanham G, Boukef K, Yacoub S, Muylle L, Mertens
G. Higher prevalence of parvovirus B19 in Belgian as
compared to Tunisian blood donors: differential implications
for prevention of transfusion transmission. Transfus Sci 1997;
18: 523-530.
- Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF,
Tiede A, Gürtler L. Pathogen safety of long-term treatments
for bleeding disorders: still relevant to current practice.
Haematologica 2013; 98: 1495-1498.
- Schmidt M, Themann A, Drexler C, Bayer M, Lanzer G,
Menichetti E, Lechner S, Wessin D, Prokoph B, Allain JP et
al. Blood donor screening for parvovirus B19 in Germany and
Austria. Transfusion 2007; 47: 1775-1782.
- Grabarczyk P, Korzeniowska J, Liszewski G, Kalińska A,
Sulkowska E, Krug-Janiak M, Kopacz A, Łetowska M, Brojer
E. Parvovirus B19 DNA testing in Polish blood donors, 2004-
2010. Przegl Epidemiol 2012; 66: 7-12.
- Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS,
Gregory KR, Dodd RY. Emerging infectious disease agents and
their potential threat to transfusion safety. Transfusion 2009;
49 (Suppl. 2): 107-109.